Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin

AIM: Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that was recently approved for treatment of metastatic breast cancer. The aim of this study was to determine the effect of rifampicin, a CYP3A4 inducer, on the plasma pharmacokinetics of eribulin in patients with solid tumours. ME...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Devriese, Lot A, Witteveen, Petronella (Els) O, Wanders, Jantien, Law, Kenneth, Edwards, Geoff, Reyderman, Larisa, Copalu, William, Peng, Fuping, Marchetti, Serena, Beijnen, Jos H, Huitema, Alwin D R, Voest, Emile E, Schellens, Jan H M
Формат: Artigo
Язык:Inglês
Опубликовано: Blackwell Science Inc 2013
Предметы:
Drug Interactions
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579265/
https://ncbi.nlm.nih.gov/pubmed/22803519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04381.x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы